How a Personalized mRNA Cancer Vaccine Is Made

Personalized mRNA cancer vaccines begin with sequencing a patient's tumor, selecting mutations likely to be visible to the immune system, and manufacturing a unique mRNA dose. The process targets remaining cancer cells, but it adds time, cost and complex quality control.

A personalized mRNA cancer vaccine is manufactured for one patient rather than drawn from a stock of identical doses. It is a treatment intended to help the immune system find cancer cells that may remain after surgery or other therapy.

1. Sequence the tumor and normal tissue

Scientists compare genetic information from the patient's tumor with normal cells, often using a blood sample. The comparison identifies mutations found in the cancer but not in healthy tissue.

2. Choose neoantigen targets

Some mutations create altered proteins called neoantigens. Computational tools rank which fragments are most likely to be displayed by the patient's cells and recognized by T cells. Only a selected set becomes part of the vaccine design.

3. Encode the targets in mRNA

The chosen instructions are combined into an mRNA sequence and packaged for delivery. After injection, cells briefly make copies of the selected targets, giving the immune system a training set that resembles markers on the patient's tumor.

4. Combine it with immune therapy

A vaccine may be paired with a checkpoint inhibitor. The vaccine identifies targets, while the other drug removes signals that restrain immune cells. The two functions are complementary, but a combination can also make it harder to isolate the contribution of each component.

The manufacturing challenge

Every patient's sequence, target list and manufactured batch are different. Production therefore requires rapid analysis, strict identity checks and quality testing. Clinical benefit must be demonstrated for each cancer and treatment setting; success in one tumor does not establish that the same platform will work in another.

First appeared in

A Personalized mRNA Vaccine Cut the Risk of Melanoma Returning

How an Electronic Nose Recognizes a Smell How Sequential Diagnostic AI Differs From a Medical Chatbot How Antisense Oligonucleotides Turn RNA Into a Drug Target How the FDA Regulates Apps Used With Prescription Drugs How Do Self-Driving Laboratories Choose Their Next Experiment? How Do AI Companies Detect Model-Distillation Attacks?